1. Home
  2. WINT vs DWTX Comparison

WINT vs DWTX Comparison

Compare WINT & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • DWTX
  • Stock Information
  • Founded
  • WINT 1992
  • DWTX 2012
  • Country
  • WINT United States
  • DWTX United States
  • Employees
  • WINT N/A
  • DWTX N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • DWTX
  • Sector
  • WINT Health Care
  • DWTX
  • Exchange
  • WINT Nasdaq
  • DWTX NYSE
  • Market Cap
  • WINT 2.9M
  • DWTX 3.1M
  • IPO Year
  • WINT 1995
  • DWTX N/A
  • Fundamental
  • Price
  • WINT $0.31
  • DWTX $2.87
  • Analyst Decision
  • WINT Hold
  • DWTX
  • Analyst Count
  • WINT 1
  • DWTX 0
  • Target Price
  • WINT $7.00
  • DWTX N/A
  • AVG Volume (30 Days)
  • WINT 1.2M
  • DWTX 23.9K
  • Earning Date
  • WINT 11-27-2024
  • DWTX 02-14-2025
  • Dividend Yield
  • WINT N/A
  • DWTX N/A
  • EPS Growth
  • WINT N/A
  • DWTX N/A
  • EPS
  • WINT N/A
  • DWTX N/A
  • Revenue
  • WINT N/A
  • DWTX N/A
  • Revenue This Year
  • WINT N/A
  • DWTX N/A
  • Revenue Next Year
  • WINT N/A
  • DWTX N/A
  • P/E Ratio
  • WINT N/A
  • DWTX N/A
  • Revenue Growth
  • WINT N/A
  • DWTX N/A
  • 52 Week Low
  • WINT $0.32
  • DWTX $1.62
  • 52 Week High
  • WINT $14.75
  • DWTX $23.50
  • Technical
  • Relative Strength Index (RSI)
  • WINT 28.66
  • DWTX N/A
  • Support Level
  • WINT $0.33
  • DWTX N/A
  • Resistance Level
  • WINT $0.42
  • DWTX N/A
  • Average True Range (ATR)
  • WINT 0.03
  • DWTX 0.00
  • MACD
  • WINT 0.02
  • DWTX 0.00
  • Stochastic Oscillator
  • WINT 1.91
  • DWTX 0.00

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About DWTX DOGWOOD THERAPEUTICS INC

Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Share on Social Networks: